Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03249792
Title Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) in the Treatment of Adults With Advance/Metastatic Solid Tumors or Lymphomas (MK-2118-001)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

Advanced Solid Tumor

lymphoma

Therapies

MK-2118 + Pembrolizumab

MK-2118

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of California San Diego Moores Cancer Center ( Site 0004) La Jolla California 92093 United States Details
UCLA ( Site 0003) Los Angeles California 90095 United States Details
University of Chicago ( Site 0002) Chicago Illinois 60637 United States Details
New York Presbyterian Hospital/Columbia University ( Site 0001) New York New York 10032 United States Details
UPMC Hillman Cancer Centers ( Site 0007) Pittsburgh Pennsylvania 15232 United States Details
Mary Crowley Cancer Research Center ( Site 0005) Dallas Texas 75230 United States Details
MD Anderson Cancer Centr. ( Site 0006) Houston Texas 77030 United States Details
Sheba Medical Center ( Site 0301) Ramat-Gan 5265601 Israel Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field